|
1
|
Cheung N, Mitchell P and Wong TY: Diabetic
retinopathy. Lancet. 376:124–136. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Klaassen I, Van Noorden CJ and
Schlingemann RO: Molecular basis of the inner blood-retinal barrier
and its breakdown in diabetic macular edema and other pathological
conditions. Prog Retin Eye Res. 34:19–48. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Leto G, Pricci F, Amadio L, Iacobini C,
Cordone S, Diaz-Horta O, Romeo G, Barsotti P, Rotella CM, di Mario
U and Pugliese G: Increased retinal endothelial cell monolayer
permeability induced by the diabetic milieu: Role of advanced
non-enzymatic glycation and polyol pathway activation. Diabetes
Metab Res Rev. 17:448–458. 2001. View
Article : Google Scholar
|
|
4
|
Segawa Y, Shirao Y, Yamagishi S, Higashide
T, Kobayashi M, Katsuno K, Iyobe A, Harada H, Sato F, Miyata H, et
al: Upregulation of retinal vascular endothelial growth factor
mRNAs in spontaneously diabetic rats without ophthalmoscopic
retinopathy. A possible participation of advanced glycation end
products in the development of the early phase of diabetic
retinopathy. Ophthalmic Res. 30:333–339. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Murata T, Nagai R, Ishibashi T, Inomuta H,
Ikeda K and Horiuchi S: The relationship between accumulation of
advanced glycation end products and expression of vascular
endothelial growth factor in human diabetic retinas. Diabetologia.
40:764–769. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lu M, Kuroki M, Amano S, Tolentino M,
Keough K, Kim I, Bucala R and Adamis AP: Advanced glycation end
products increase retinal vascular endothelial growth factor
expression. J Clin Invest. 101:1219–1224. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Antonetti DA, Barber AJ, Khin S, Lieth E,
Tarbell JM and Gardner TW: Vascular permeability in experimental
diabetes is associated with reduced endothelial occludin content:
Vascular endothelial growth factor decreases occludin in retinal
endothelial cells. Penn State Retina Research Group. Diabetes.
47:1953–1959. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kim J, Lee YM, Kim CS, Sohn E, Jo K, Shin
SD and Kim JS: Ethyl pyruvate prevents methyglyoxal-induced retinal
vascular injury in rats. J Diabetes Res. 2013:4608202013.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hsieh CF and Chaw SM: Osteomeles
schwerinae C. K. Schneid. (Rosaceae): A new record for the flora of
Taiwan. Bot Bull Acad Sin. 37:281–285. 1996.
|
|
10
|
Lee J, Jang DS, Yoo NH, Lee YM, Kim JH and
Kim JS: Single-step separation of bioactive flavonol glucosides
from Osteomeles schwerinae by high-speed counter-current
chromatography. J Sep Sci. 33:582–586. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kim JS, Kim J, Kim CS, Kim YS, Shon E,
Jung D, Lee YM, Jung SH and Lee YR: Phenyl derivatives or
pharmaceutically acceptable salts thereof, method for preparing
same, and composition comprising same as active ingredients for
preventing, improving or treating diseases related to vascular
endothelial cells or diabetes. Patents. 2013
|
|
12
|
Vlassara H, Striker LJ, Teichberg S, Fuh
H, Li YM and Steffes M: Advanced glycation end products induce
glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad
Sci USA. 91:11704–11708. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kim J, Kim KM, Kim CS, Sohn E, Lee YM, Jo
K and Kim JS: Puerarin inhibits the retinal pericyte apoptosis
induced by advanced glycation end products in vitro and in vivo by
inhibiting NADPH oxidase-related oxidative stress. Free Radic Biol
Med. 53:357–365. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sander B, Larsen M, Engler C,
Lund-Andersen H and Parving HH: Early changes in diabetic
retinopathy: Capillary loss and blood-retina barrier permeability
in relation to metabolic control. Acta Ophthalmol (Copenh).
72:553–559. 1994. View Article : Google Scholar
|
|
15
|
Giebel SJ, Menicucci G, McGuire PG and Das
A: Matrix metal-loproteinases in early diabetic retinopathy and
their role in alteration of the blood-retinal barrier. Lab Invest.
85:597–607. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Stitt AW: Advanced glycation: An important
pathological event in diabetic and age related ocular disease. Br J
Ophthalmol. 85:746–753. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kim J, Kim CS, Sohn E, Lee YM, Jo K, Shin
SD and Kim JS: Aminoguanidine protects against apoptosis of retinal
ganglion cells in Zucker diabetic fatty rats. Eur Rev Med Pharmacol
Sci. 18:1573–1578. 2014.PubMed/NCBI
|
|
18
|
Thornalley PJ: Use of aminoguanidine
(Pimagedine) to prevent the formation of advanced glycation
endproducts. Arch Biochem Biophys. 419:31–40. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yoon J, Lee H, Chang HB, Choi H, Kim YS,
Rho YK, Seong S, Choi DH, Park D and Ku B: DW1029 M, a novel
botanical drug candidate, inhibits advanced glycation end-product
formation, rat lens aldose reductase activity and TGF-β 1
signaling. Am J Physiol Renal Physiol. 306:F1161–F1170. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kim J, Jeong IH, Kim CS, Lee YM, Kim JM
and Kim JS: Chlorogenic acid inhibits the formation of advanced
glycation end products and associated protein cross-linking. Arch
Pharm Res. 34:495–500. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yan H, Guo Y, Zhang J, Ding Z, Ha W and
Harding JJ: Effect of carnosine, aminoguanidine and aspirin drops
on the prevention of cataracts in diabetic rats. Mol Vis.
14:2282–2291. 2008.
|
|
22
|
Makita Z, Vlassara H, Cerami A and Bucala
R: Immunochemical detection of advanced glycosylation end products
in vivo. J Biol Chem. 267:5133–5138. 1992.PubMed/NCBI
|
|
23
|
Stitt AW, Bhaduri T, McMullen CB, Gardiner
TA and Archer DB: Advanced glycation end products induce
blood-retinal barrier dysfunction in normoglycemic rats. Mol Cell
Biol Res Commun. 3:380–388. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Vlassara H, Fuh H, Makita Z, Krungkrai S,
Cerami A and Bucala R: Exogenous advanced glycosylation end
products induce complex vascular dysfunction in normal animals: A
model for diabetic and aging complications. Proc Natl Acad Sci USA.
89:12043–12047. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wautier JL, Zoukourian C, Chappey O,
Wautier MP, Guillausseau PJ, Cao R, Hori O, Stern D and Schmidt AM:
Receptor-mediated endothelial cell dysfunction in diabetic
vasculopathy. Soluble receptor for advanced glycation end products
blocks hyperpermeability in diabetic rats. J Clin Invest.
97:238–243. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xu HZ and Le YZ: Significance of outer
blood-retina barrier breakdown in diabetes and ischemia. Invest
Ophthalmol Vis Sci. 52:2160–2164. 2011. View Article : Google Scholar :
|
|
27
|
Sheikpranbabu S, Kalishwaralal K, Lee KJ,
Vaidyanathan R, Eom SH and Gurunathan S: The inhibition of advanced
glycation end-products-induced retinal vascular permeability by
silver nanoparticles. Biomaterials. 31:2260–2271. 2010. View Article : Google Scholar
|
|
28
|
Furuse M, Hirase T, Itoh M, Nagafuchi A,
Yonemura S and Tsukita S and Tsukita S: Occludin: A novel integral
membrane protein localizing at tight junctions. J Cell Biol.
123:1777–1788. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bucolo C, Ward KW, Mazzon E, Cuzzocrea S
and Drago F: Protective effects of a coumarin derivative in
diabetic rats. Invest Ophthalmol Vis Sci. 50:3846–3852. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kim J, Kim CS, Lee IS, Lee YM, Sohn E, Jo
K, Kim JH and Kim JS: Extract of Litsea japonica ameliorates
blood-retinal barrier breakdown in db/db mice. Endocrine.
46:462–469. 2014. View Article : Google Scholar
|
|
31
|
Schulzke JD, Gitter AH, Mankertz J,
Spiegel S, Seidler U, Amasheh S, Saitou M, Tsukita S and Fromm M:
Epithelial transport and barrier function in occludin-deficient
mice. Biochim Biophys Acta. 1669:34–42. 2005. View Article : Google Scholar : PubMed/NCBI
|
